New Hampshire Rx data case appeal

15 January 2009

Two of the world's largest health data providers, IMS Health and SDI, have filed a motion with the US First Circuit Court of Appeals to  request a rehearing of the decision to overturn a New Hampshire US  District Court ruling that struck down the State's law banning the  commercial use of prescriber-identifiable data (Marketletters passim).  SDI took over Verispan, one of the original three firms contesting the  data-mining restrictions, in July 2008.

In a joint statement, the firms said: "we have reviewed the First  Circuit's decision and believe that there is a strong basis for a  rehearing. We strongly believe the First Amendment [of the US  Constitution] protects the full dissemination of prescriber-identifiable  data, which is vital to efforts to improve the quality, efficiency and  safety of our health care system. Further, we agree with prior decisions  that without these data the potential exists to compromise patient  care."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight